Shuaiying Cui PhD

Associate Professor, Hematology & Medical Oncology

650 Albany St | (617) 638-7163
shuaiyin@bu.edu

Sections

Hematology & Medical Oncology

Centers

Center of Excellence in Sickle Cell Disease

Biography

Dr. Cui's research has focused on the development of novel agents that can elicit developmental stage-specific gene silencing or reprogramming in hematopoietic stem cells and progenitors through a series of epigenetic chromatin modifications by nucleosome remodeling, histone deacetylation and demethylation. Such agents can be applied to the treatment of the patients with hematologic disorders such as sickle cell disease and beta-thalassemia, as well as acute myeloid leukemia (Blood cancer), which arise from congenital defects in genome. The findings from these preclinical studies could also help to establish therapeutic indications in other hematological malignancies.

Websites

BU Profile

Cui Lab

My NCBI

2023-wing-tat-lee-award-recipients

Google Scholar

Education

Genetics & Genomics, PhD, University of Science and Technology of China

Biology, BS, Anhui University

Publications

Published on 7/31/2024

Sun Y, Benmhammed H, Al Abdullatif S, Habara A, Fu E, Brady J, Williams C, Ilinski A, Sharma A, Mahdaviani K, Alekseyev YO, Campbell JD, Steinberg MH, Cui S. PGC-1a agonism induces fetal hemoglobin and exerts antisickling effects in sickle cell disease. Sci Adv. 2024 Aug 02; 10(31):eadn8750. PMID: 39083598.

PubMed

Published on 2/4/2022

Sun Y, Habara A, Le CQ, Nguyen N, Chen R, Murphy GJ, Chui DHK, Steinberg MH, Cui S. Pharmacologic induction of PGC-1a stimulates fetal haemoglobin gene expression. Br J Haematol. 2022 Apr; 197(1):97-109. PMID: 35118652.

PubMed

Published on 1/26/2022

Aygun B, Bello A, Thompson AA, Davis L, Sun Y, Luo HY, Cui S, Chui DHK. Clinical phenotypes of three children with sickle cell disease caused by HbS/Sicilian (dß)0 -thalassemia deletion. Am J Hematol. 2022 04; 97(4):E156-E158. PMID: 35045200.

PubMed

Published on 9/27/2021

Li X, Chen M, Liu B, Lu P, Lv X, Zhao X, Cui S, Xu P, Nakamura Y, Kurita R, Chen B, Huang DCS, Liu DP, Liu M, Zhao Q. Transcriptional silencing of fetal hemoglobin expression by NonO. Nucleic Acids Res. 2021 09 27; 49(17):9711-9723. PMID: 34379783.

PubMed

Published on 4/16/2019

Le CQ, Myers G, Habara A, Jearawiriyapaisarn N, Murphy GJ, Chui DHK, Steinberg MH, Engel JD, Cui S. Inhibition of LSD1 by small molecule inhibitors stimulates fetal hemoglobin synthesis. Blood. 2019 05 30; 133(22):2455-2459. PMID: 30992270.

PubMed

Published on 1/31/2018

Tang B, Wang S, Wang SG, Wang HJ, Zhang JY, Cui SY. Invertebrate Trehalose-6-Phosphate Synthase Gene: Genetic Architecture, Biochemistry, Physiological Function, and Potential Applications. Front Physiol. 2018; 9:30. PMID: 29445344.

PubMed

Published on 11/29/2017

Morrison TA, Wilcox I, Luo HY, Farrell JJ, Kurita R, Nakamura Y, Murphy GJ, Cui S, Steinberg MH, Chui DHK. A long noncoding RNA from the HBS1L-MYB intergenic region on chr6q23 regulates human fetal hemoglobin expression. Blood Cells Mol Dis. 2018 03; 69:1-9. PMID: 29227829.

PubMed

Published on 9/1/2017

de Medeiros AS, Wyman AR, Alaamery MA, Allain C, Ivey FD, Wang L, Le H, Morken JP, Habara A, Le C, Cui S, Lerner A, Hoffman CS. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays. Cell Signal. 2017 Dec; 40:73-80. PMID: 28867658.

PubMed

Published on 2/24/2017

Jagadeeswaran R, Vazquez BA, Thiruppathi M, Ganesh BB, Ibanez V, Cui S, Engel JD, Diamond AM, Molokie RE, DeSimone J, Lavelle D, Rivers A. Pharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cells of sickle cell disease. Exp Hematol. 2017 06; 50:46-52. PMID: 28238805.

PubMed

Published on 1/1/2017

Cui S, Engel JD. Reactivation of Fetal Hemoglobin for Treating ß-Thalassemia and Sickle Cell Disease. Adv Exp Med Biol. 2017; 1013:177-202. PMID: 29127681.

PubMed

View full list of 26 publications.